Noxopharm 2026 AGM Chair’s Address Sydney, 17 November 2026: Innovative biotech company Noxopharm Limited (ASX:NOX) provides Noxopharm Non-Executive Chairman Mr Frederick Bart’s address to the 2026 Annual General Meeting of Shareholders. -ENDS- About Noxopharm Noxopharm Limited (ASX:NOX) is a...
Noxopharm 2026 AGM Chair's Address
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The address highlights the company's progress, including the completion of a clinical safety trial for its autoimmune drug candidate, SOF-SKN, which is set to enter testing on lupus patients soon. Additionally, the company is advancing its cancer program and has received recognition for its research published in a leading scientific journal. The Chair expresses gratitude to shareholders for their support, particularly during a recent capital raise, and emphasizes the company's potential for future achievements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
In the deck
Earlier from Noxopharm
- Noxopharm receives $1.4 million R&D tax incentive rebate
- Noxopharm Investor Webinar
- Cleansing Statement
- Application for quotation of securities - NOX
- Proposed issue of securities - NOX
Later from Noxopharm
- Noxopharm 2026 AGM Corporate Presentation
- Results of Meeting
- Notice of Extraordinary General Meeting/Proxy Form
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm